Symlin

Active Ingredient(s): Pramlintide
FDA Approved: * March 16, 2005
Pharm Company: * AMYLIN
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Symlin Overview

Pramlintide (trade name Symlin) is an injectable amylin analogue drug for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca).[1] Pramlintide is sold as an acetate salt. Contents 1 Pharmacology 2 Approval 3 Design and structure 4 References 5 External links Pharmacology Pramlintide is an analogue of amylin, a small peptide hormone that is released into the bloodstream by the β cells of the pancreas alon...

Read more Symlin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pramlintide

Recent Symlin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Symlin: (1 result)

Sorted by National Drug Code

• 66780-110 Symlin 600 ug/ml Subcutaneous Injection by Amylin Pharmaceuticals, Inc.

Other drugs which contain Pramlintide or a similar ingredient: (1 result)

• PRAMLINTIDE

Related Symlin Topics: